HemoGenyx Pharmaceuticals Plc (GB:HEMO) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hemogenyx Pharmaceuticals has received IRB approval to begin a Phase I clinical trial of its lead therapy, HEMO-CAR-T, aimed at treating relapsed/refractory acute myeloid leukemia. This marks a significant step for the company in advancing a potentially groundbreaking treatment for a type of cancer with limited options. Investors may find this development promising as it could impact treatment and survival rates for AML.
For further insights into GB:HEMO stock, check out TipRanks’ Stock Analysis page.